nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—ABCB1—peripheral nervous system neoplasm	0.304	1	CbGaD
Loperamide—CYP2B6—Tretinoin—peripheral nervous system neoplasm	0.0593	0.161	CbGbCtD
Loperamide—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0449	0.122	CbGbCtD
Loperamide—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0327	0.0885	CbGbCtD
Loperamide—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0327	0.0885	CbGbCtD
Loperamide—CYP2B6—Cisplatin—peripheral nervous system neoplasm	0.0254	0.0687	CbGbCtD
Loperamide—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0227	0.0614	CbGbCtD
Loperamide—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0196	0.053	CbGbCtD
Loperamide—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0189	0.0512	CbGbCtD
Loperamide—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0182	0.0493	CbGbCtD
Loperamide—CYP2B6—Doxorubicin—peripheral nervous system neoplasm	0.017	0.0461	CbGbCtD
Loperamide—POMC—vagus nerve—peripheral nervous system neoplasm	0.015	0.171	CbGeAlD
Loperamide—ABCB1—Vincristine—peripheral nervous system neoplasm	0.014	0.0378	CbGbCtD
Loperamide—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.013	0.0352	CbGbCtD
Loperamide—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0128	0.0346	CbGbCtD
Loperamide—POMC—cranial nerve—peripheral nervous system neoplasm	0.0114	0.13	CbGeAlD
Loperamide—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00873	0.0236	CbGbCtD
Loperamide—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00837	0.0226	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00822	0.0223	CbGbCtD
Loperamide—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00767	0.0207	CbGbCtD
Loperamide—POMC—nerve—peripheral nervous system neoplasm	0.00584	0.0667	CbGeAlD
Loperamide—POMC—ganglion—peripheral nervous system neoplasm	0.00577	0.0659	CbGeAlD
Loperamide—CACNA1A—nerve—peripheral nervous system neoplasm	0.00558	0.0637	CbGeAlD
Loperamide—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00523	0.0142	CbGbCtD
Loperamide—CALM1—trigeminal nerve—peripheral nervous system neoplasm	0.00435	0.0496	CbGeAlD
Loperamide—OPRD1—ganglion—peripheral nervous system neoplasm	0.00318	0.0363	CbGeAlD
Loperamide—CALM1—cranial nerve—peripheral nervous system neoplasm	0.0031	0.0354	CbGeAlD
Loperamide—CALM2—pons—peripheral nervous system neoplasm	0.00308	0.0351	CbGeAlD
Loperamide—CALM1—pons—peripheral nervous system neoplasm	0.00306	0.035	CbGeAlD
Loperamide—POMC—brainstem—peripheral nervous system neoplasm	0.00251	0.0286	CbGeAlD
Loperamide—CACNA1A—brainstem—peripheral nervous system neoplasm	0.00239	0.0273	CbGeAlD
Loperamide—OPRM1—nerve—peripheral nervous system neoplasm	0.0022	0.0251	CbGeAlD
Loperamide—OPRM1—ganglion—peripheral nervous system neoplasm	0.00217	0.0248	CbGeAlD
Loperamide—CALM2—nerve—peripheral nervous system neoplasm	0.0016	0.0182	CbGeAlD
Loperamide—CALM1—nerve—peripheral nervous system neoplasm	0.00159	0.0181	CbGeAlD
Loperamide—CALM2—ganglion—peripheral nervous system neoplasm	0.00158	0.018	CbGeAlD
Loperamide—CALM1—ganglion—peripheral nervous system neoplasm	0.00157	0.0179	CbGeAlD
Loperamide—POMC—cerebellum—peripheral nervous system neoplasm	0.00124	0.0141	CbGeAlD
Loperamide—CACNA1A—cerebellum—peripheral nervous system neoplasm	0.00118	0.0135	CbGeAlD
Loperamide—CALM3—trigeminal ganglion—peripheral nervous system neoplasm	0.000985	0.0113	CbGeAlD
Loperamide—OPRM1—brainstem—peripheral nervous system neoplasm	0.000944	0.0108	CbGeAlD
Loperamide—CALM3—parotid gland—peripheral nervous system neoplasm	0.000929	0.0106	CbGeAlD
Loperamide—CALM2—trigeminal ganglion—peripheral nervous system neoplasm	0.000774	0.00884	CbGeAlD
Loperamide—CALM1—trigeminal ganglion—peripheral nervous system neoplasm	0.00077	0.00879	CbGeAlD
Loperamide—CALM2—parotid gland—peripheral nervous system neoplasm	0.00073	0.00833	CbGeAlD
Loperamide—CALM2—brainstem—peripheral nervous system neoplasm	0.000685	0.00782	CbGeAlD
Loperamide—CALM1—brainstem—peripheral nervous system neoplasm	0.000682	0.00778	CbGeAlD
Loperamide—OPRK1—cerebellum—peripheral nervous system neoplasm	0.000654	0.00747	CbGeAlD
Loperamide—Dry mouth—Isotretinoin—peripheral nervous system neoplasm	0.000473	0.00387	CcSEcCtD
Loperamide—Urinary tract disorder—Vincristine—peripheral nervous system neoplasm	0.000471	0.00385	CcSEcCtD
Loperamide—Erythema multiforme—Alitretinoin—peripheral nervous system neoplasm	0.000468	0.00383	CcSEcCtD
Loperamide—Anaphylactic shock—Topotecan—peripheral nervous system neoplasm	0.000468	0.00383	CcSEcCtD
Loperamide—Urethral disorder—Vincristine—peripheral nervous system neoplasm	0.000467	0.00382	CcSEcCtD
Loperamide—Anaphylactic shock—Isotretinoin—peripheral nervous system neoplasm	0.000464	0.0038	CcSEcCtD
Loperamide—Anaphylactic shock—Tretinoin—peripheral nervous system neoplasm	0.000464	0.0038	CcSEcCtD
Loperamide—Nervous system disorder—Topotecan—peripheral nervous system neoplasm	0.000459	0.00375	CcSEcCtD
Loperamide—Anaphylactic shock—Melphalan—peripheral nervous system neoplasm	0.000458	0.00375	CcSEcCtD
Loperamide—Nervous system disorder—Tretinoin—peripheral nervous system neoplasm	0.000455	0.00372	CcSEcCtD
Loperamide—Nervous system disorder—Isotretinoin—peripheral nervous system neoplasm	0.000455	0.00372	CcSEcCtD
Loperamide—Skin disorder—Topotecan—peripheral nervous system neoplasm	0.000454	0.00372	CcSEcCtD
Loperamide—Skin disorder—Tretinoin—peripheral nervous system neoplasm	0.000451	0.00369	CcSEcCtD
Loperamide—Skin disorder—Isotretinoin—peripheral nervous system neoplasm	0.000451	0.00369	CcSEcCtD
Loperamide—Skin disorder—Melphalan—peripheral nervous system neoplasm	0.000445	0.00364	CcSEcCtD
Loperamide—CALM3—cerebellum—peripheral nervous system neoplasm	0.00043	0.00491	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Etoposide—peripheral nervous system neoplasm	0.000427	0.00349	CcSEcCtD
Loperamide—Flatulence—Alitretinoin—peripheral nervous system neoplasm	0.000424	0.00347	CcSEcCtD
Loperamide—Urinary tract disorder—Cisplatin—peripheral nervous system neoplasm	0.000416	0.00341	CcSEcCtD
Loperamide—Urethral disorder—Cisplatin—peripheral nervous system neoplasm	0.000413	0.00338	CcSEcCtD
Loperamide—Somnolence—Isotretinoin—peripheral nervous system neoplasm	0.000412	0.00337	CcSEcCtD
Loperamide—Somnolence—Tretinoin—peripheral nervous system neoplasm	0.000412	0.00337	CcSEcCtD
Loperamide—Dyspepsia—Topotecan—peripheral nervous system neoplasm	0.000412	0.00337	CcSEcCtD
Loperamide—Dyspepsia—Isotretinoin—peripheral nervous system neoplasm	0.000408	0.00334	CcSEcCtD
Loperamide—Dyspepsia—Tretinoin—peripheral nervous system neoplasm	0.000408	0.00334	CcSEcCtD
Loperamide—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.000404	0.0033	CcSEcCtD
Loperamide—Fatigue—Topotecan—peripheral nervous system neoplasm	0.000403	0.0033	CcSEcCtD
Loperamide—Dyspepsia—Melphalan—peripheral nervous system neoplasm	0.000403	0.0033	CcSEcCtD
Loperamide—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.0004	0.00328	CcSEcCtD
Loperamide—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.0004	0.00328	CcSEcCtD
Loperamide—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.0004	0.00327	CcSEcCtD
Loperamide—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.0004	0.00327	CcSEcCtD
Loperamide—Constipation—Topotecan—peripheral nervous system neoplasm	0.0004	0.00327	CcSEcCtD
Loperamide—Constipation—Tretinoin—peripheral nervous system neoplasm	0.000397	0.00325	CcSEcCtD
Loperamide—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.000397	0.00325	CcSEcCtD
Loperamide—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.000395	0.00323	CcSEcCtD
Loperamide—Fatigue—Melphalan—peripheral nervous system neoplasm	0.000395	0.00323	CcSEcCtD
Loperamide—Discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000391	0.0032	CcSEcCtD
Loperamide—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.000382	0.00313	CcSEcCtD
Loperamide—Urinary tract disorder—Etoposide—peripheral nervous system neoplasm	0.000381	0.00312	CcSEcCtD
Loperamide—Immune system disorder—Cisplatin—peripheral nervous system neoplasm	0.000381	0.00312	CcSEcCtD
Loperamide—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.000379	0.0031	CcSEcCtD
Loperamide—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.000379	0.0031	CcSEcCtD
Loperamide—Urethral disorder—Etoposide—peripheral nervous system neoplasm	0.000379	0.0031	CcSEcCtD
Loperamide—Loss of consciousness—Alitretinoin—peripheral nervous system neoplasm	0.000379	0.0031	CcSEcCtD
Loperamide—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000378	0.00432	CbGeAlD
Loperamide—Urticaria—Topotecan—peripheral nervous system neoplasm	0.000371	0.00304	CcSEcCtD
Loperamide—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.00037	0.00302	CcSEcCtD
Loperamide—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.000368	0.00301	CcSEcCtD
Loperamide—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.000368	0.00301	CcSEcCtD
Loperamide—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.000367	0.003	CcSEcCtD
Loperamide—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.000367	0.003	CcSEcCtD
Loperamide—Erythema multiforme—Etoposide—peripheral nervous system neoplasm	0.000365	0.00299	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000364	0.00298	CcSEcCtD
Loperamide—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000364	0.00298	CcSEcCtD
Loperamide—Discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000362	0.00296	CcSEcCtD
Loperamide—Flatulence—Cisplatin—peripheral nervous system neoplasm	0.000362	0.00296	CcSEcCtD
Loperamide—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.000359	0.00293	CcSEcCtD
Loperamide—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.000352	0.00288	CcSEcCtD
Loperamide—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.000349	0.00285	CcSEcCtD
Loperamide—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000345	0.00282	CcSEcCtD
Loperamide—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000344	0.00282	CcSEcCtD
Loperamide—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000342	0.0028	CcSEcCtD
Loperamide—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000342	0.0028	CcSEcCtD
Loperamide—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000341	0.00279	CcSEcCtD
Loperamide—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.000339	0.00277	CcSEcCtD
Loperamide—CALM2—cerebellum—peripheral nervous system neoplasm	0.000338	0.00385	CbGeAlD
Loperamide—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000337	0.00276	CcSEcCtD
Loperamide—CALM1—cerebellum—peripheral nervous system neoplasm	0.000336	0.00384	CbGeAlD
Loperamide—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000335	0.00274	CcSEcCtD
Loperamide—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000333	0.00272	CcSEcCtD
Loperamide—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000333	0.00272	CcSEcCtD
Loperamide—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000332	0.00272	CcSEcCtD
Loperamide—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000331	0.00271	CcSEcCtD
Loperamide—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000328	0.00269	CcSEcCtD
Loperamide—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000328	0.00268	CcSEcCtD
Loperamide—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000328	0.00268	CcSEcCtD
Loperamide—Dermatitis bullous—Epirubicin—peripheral nervous system neoplasm	0.000327	0.00268	CcSEcCtD
Loperamide—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000327	0.00267	CcSEcCtD
Loperamide—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000324	0.00265	CcSEcCtD
Loperamide—Anaphylactoid reaction—Epirubicin—peripheral nervous system neoplasm	0.000323	0.00265	CcSEcCtD
Loperamide—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00032	0.00262	CcSEcCtD
Loperamide—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000317	0.0026	CcSEcCtD
Loperamide—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000317	0.0026	CcSEcCtD
Loperamide—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000313	0.00256	CcSEcCtD
Loperamide—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000313	0.00256	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.00031	0.00254	CcSEcCtD
Loperamide—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.00031	0.00254	CcSEcCtD
Loperamide—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000309	0.00253	CcSEcCtD
Loperamide—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000309	0.00253	CcSEcCtD
Loperamide—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000309	0.00253	CcSEcCtD
Loperamide—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000307	0.00351	CbGeAlD
Loperamide—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000307	0.00251	CcSEcCtD
Loperamide—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000307	0.00251	CcSEcCtD
Loperamide—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000303	0.00248	CcSEcCtD
Loperamide—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000303	0.00248	CcSEcCtD
Loperamide—Dermatitis bullous—Doxorubicin—peripheral nervous system neoplasm	0.000303	0.00248	CcSEcCtD
Loperamide—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000301	0.00246	CcSEcCtD
Loperamide—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.0003	0.00245	CcSEcCtD
Loperamide—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.0003	0.00245	CcSEcCtD
Loperamide—Anaphylactoid reaction—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.00245	CcSEcCtD
Loperamide—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000297	0.00243	CcSEcCtD
Loperamide—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000296	0.00242	CcSEcCtD
Loperamide—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000295	0.00241	CcSEcCtD
Loperamide—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000295	0.00241	CcSEcCtD
Loperamide—Rash—Topotecan—peripheral nervous system neoplasm	0.000295	0.00241	CcSEcCtD
Loperamide—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000295	0.00241	CcSEcCtD
Loperamide—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000294	0.0024	CcSEcCtD
Loperamide—Headache—Topotecan—peripheral nervous system neoplasm	0.000293	0.0024	CcSEcCtD
Loperamide—Rash—Tretinoin—peripheral nervous system neoplasm	0.000292	0.00239	CcSEcCtD
Loperamide—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000292	0.00239	CcSEcCtD
Loperamide—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000292	0.00239	CcSEcCtD
Loperamide—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000292	0.00239	CcSEcCtD
Loperamide—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000292	0.00239	CcSEcCtD
Loperamide—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000292	0.00239	CcSEcCtD
Loperamide—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000291	0.00238	CcSEcCtD
Loperamide—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000291	0.00238	CcSEcCtD
Loperamide—Headache—Tretinoin—peripheral nervous system neoplasm	0.000291	0.00238	CcSEcCtD
Loperamide—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000291	0.00238	CcSEcCtD
Loperamide—Constipation—Vincristine—peripheral nervous system neoplasm	0.00029	0.00237	CcSEcCtD
Loperamide—Rash—Melphalan—peripheral nervous system neoplasm	0.000289	0.00236	CcSEcCtD
Loperamide—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000288	0.00236	CcSEcCtD
Loperamide—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000287	0.00235	CcSEcCtD
Loperamide—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000286	0.00234	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000284	0.00233	CcSEcCtD
Loperamide—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000283	0.00231	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000282	0.00231	CcSEcCtD
Loperamide—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000279	0.00229	CcSEcCtD
Loperamide—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000279	0.00228	CcSEcCtD
Loperamide—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000278	0.00227	CcSEcCtD
Loperamide—Nausea—Topotecan—peripheral nervous system neoplasm	0.000278	0.00227	CcSEcCtD
Loperamide—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000277	0.00227	CcSEcCtD
Loperamide—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000276	0.00225	CcSEcCtD
Loperamide—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000276	0.00225	CcSEcCtD
Loperamide—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000274	0.00225	CcSEcCtD
Loperamide—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.000272	0.00223	CcSEcCtD
Loperamide—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000272	0.00223	CcSEcCtD
Loperamide—Nausea—Melphalan—peripheral nervous system neoplasm	0.000272	0.00223	CcSEcCtD
Loperamide—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000268	0.00219	CcSEcCtD
Loperamide—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000267	0.00218	CcSEcCtD
Loperamide—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000264	0.00216	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.00213	CcSEcCtD
Loperamide—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000259	0.00212	CcSEcCtD
Loperamide—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000259	0.00212	CcSEcCtD
Loperamide—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000259	0.00212	CcSEcCtD
Loperamide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000252	0.00206	CcSEcCtD
Loperamide—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000252	0.00206	CcSEcCtD
Loperamide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.00025	0.00204	CcSEcCtD
Loperamide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000249	0.00203	CcSEcCtD
Loperamide—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000244	0.002	CcSEcCtD
Loperamide—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000243	0.00199	CcSEcCtD
Loperamide—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000241	0.00197	CcSEcCtD
Loperamide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000241	0.00197	CcSEcCtD
Loperamide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000241	0.00197	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000239	0.00196	CcSEcCtD
Loperamide—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000239	0.00196	CcSEcCtD
Loperamide—Toremifene—ABCB1—peripheral nervous system neoplasm	0.000238	0.221	CrCbGaD
Loperamide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000237	0.00194	CcSEcCtD
Loperamide—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000237	0.00194	CcSEcCtD
Loperamide—Constipation—Etoposide—peripheral nervous system neoplasm	0.000235	0.00192	CcSEcCtD
Loperamide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000232	0.0019	CcSEcCtD
Loperamide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000232	0.0019	CcSEcCtD
Loperamide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000225	0.00184	CcSEcCtD
Loperamide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000224	0.00184	CcSEcCtD
Loperamide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000224	0.00183	CcSEcCtD
Loperamide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000224	0.00183	CcSEcCtD
Loperamide—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000223	0.00183	CcSEcCtD
Loperamide—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000222	0.00181	CcSEcCtD
Loperamide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000221	0.00181	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000221	0.00181	CcSEcCtD
Loperamide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000221	0.00181	CcSEcCtD
Loperamide—Headache—Alitretinoin—peripheral nervous system neoplasm	0.00022	0.0018	CcSEcCtD
Loperamide—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000218	0.00178	CcSEcCtD
Loperamide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000217	0.00177	CcSEcCtD
Loperamide—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000215	0.00176	CcSEcCtD
Loperamide—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000215	0.00176	CcSEcCtD
Loperamide—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000214	0.00175	CcSEcCtD
Loperamide—Rash—Vincristine—peripheral nervous system neoplasm	0.000214	0.00175	CcSEcCtD
Loperamide—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000213	0.00175	CcSEcCtD
Loperamide—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000212	0.00174	CcSEcCtD
Loperamide—Headache—Vincristine—peripheral nervous system neoplasm	0.000212	0.00174	CcSEcCtD
Loperamide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000209	0.00171	CcSEcCtD
Loperamide—Fexofenadine—ABCB1—peripheral nervous system neoplasm	0.000208	0.193	CrCbGaD
Loperamide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000205	0.00168	CcSEcCtD
Loperamide—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000205	0.00167	CcSEcCtD
Loperamide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000202	0.00165	CcSEcCtD
Loperamide—Nausea—Vincristine—peripheral nervous system neoplasm	0.000201	0.00165	CcSEcCtD
Loperamide—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.00162	CcSEcCtD
Loperamide—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000197	0.00161	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.00161	CcSEcCtD
Loperamide—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000196	0.0016	CcSEcCtD
Loperamide—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000194	0.00159	CcSEcCtD
Loperamide—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00019	0.00156	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000189	0.00155	CcSEcCtD
Loperamide—Rash—Cisplatin—peripheral nervous system neoplasm	0.000189	0.00155	CcSEcCtD
Loperamide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000189	0.00154	CcSEcCtD
Loperamide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000188	0.00154	CcSEcCtD
Loperamide—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000186	0.00213	CbGeAlD
Loperamide—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000186	0.00152	CcSEcCtD
Loperamide—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000181	0.00148	CcSEcCtD
Loperamide—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.00148	CcSEcCtD
Loperamide—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000178	0.00146	CcSEcCtD
Loperamide—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000174	0.00143	CcSEcCtD
Loperamide—Rash—Etoposide—peripheral nervous system neoplasm	0.000173	0.00142	CcSEcCtD
Loperamide—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000173	0.00141	CcSEcCtD
Loperamide—Headache—Etoposide—peripheral nervous system neoplasm	0.000172	0.00141	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000172	0.00141	CcSEcCtD
Loperamide—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000166	0.00136	CcSEcCtD
Loperamide—Nausea—Etoposide—peripheral nervous system neoplasm	0.000163	0.00133	CcSEcCtD
Loperamide—Clotrimazole—ABCB1—peripheral nervous system neoplasm	0.000161	0.149	CrCbGaD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000159	0.0013	CcSEcCtD
Loperamide—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000159	0.0013	CcSEcCtD
Loperamide—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000157	0.00128	CcSEcCtD
Loperamide—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000154	0.00126	CcSEcCtD
Loperamide—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.00125	CcSEcCtD
Loperamide—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000151	0.00123	CcSEcCtD
Loperamide—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000149	0.00122	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.00121	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.0012	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.00119	CcSEcCtD
Loperamide—Haloperidol—ABCB1—peripheral nervous system neoplasm	0.000145	0.134	CrCbGaD
Loperamide—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000142	0.00116	CcSEcCtD
Loperamide—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.00114	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.00113	CcSEcCtD
Loperamide—Fentanyl—ABCB1—peripheral nervous system neoplasm	0.000138	0.127	CrCbGaD
Loperamide—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000137	0.00112	CcSEcCtD
Loperamide—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000135	0.00111	CcSEcCtD
Loperamide—ABCB1—cerebellum—peripheral nervous system neoplasm	0.000134	0.00153	CbGeAlD
Loperamide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000133	0.00109	CcSEcCtD
Loperamide—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000133	0.00108	CcSEcCtD
Loperamide—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000132	0.00108	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.00104	CcSEcCtD
Loperamide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000126	0.00103	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.00102	CcSEcCtD
Loperamide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.00101	CcSEcCtD
Loperamide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.001	CcSEcCtD
Loperamide—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000122	0.001	CcSEcCtD
Loperamide—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000996	CcSEcCtD
Loperamide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000995	CcSEcCtD
Loperamide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000952	CcSEcCtD
Loperamide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000927	CcSEcCtD
Loperamide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000925	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.00092	CcSEcCtD
Loperamide—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000903	CcSEcCtD
Loperamide—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000109	0.00089	CcSEcCtD
Loperamide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000861	CcSEcCtD
Loperamide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000858	CcSEcCtD
Loperamide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000835	CcSEcCtD
Loperamide—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000832	CcSEcCtD
Loperamide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000824	CcSEcCtD
Loperamide—Vomiting—Epirubicin—peripheral nervous system neoplasm	9.78e-05	0.0008	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	9.74e-05	0.000797	CcSEcCtD
Loperamide—Rash—Epirubicin—peripheral nervous system neoplasm	9.7e-05	0.000793	CcSEcCtD
Loperamide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	9.69e-05	0.000793	CcSEcCtD
Loperamide—Headache—Epirubicin—peripheral nervous system neoplasm	9.64e-05	0.000788	CcSEcCtD
Loperamide—Tamoxifen—ABCB1—peripheral nervous system neoplasm	9.52e-05	0.0882	CrCbGaD
Loperamide—Methadone—ABCB1—peripheral nervous system neoplasm	9.43e-05	0.0874	CrCbGaD
Loperamide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	9.41e-05	0.00077	CcSEcCtD
Loperamide—Nausea—Epirubicin—peripheral nervous system neoplasm	9.14e-05	0.000747	CcSEcCtD
Loperamide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	9.05e-05	0.00074	CcSEcCtD
Loperamide—Rash—Doxorubicin—peripheral nervous system neoplasm	8.97e-05	0.000734	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	8.97e-05	0.000734	CcSEcCtD
Loperamide—Headache—Doxorubicin—peripheral nervous system neoplasm	8.92e-05	0.000729	CcSEcCtD
Loperamide—Nausea—Doxorubicin—peripheral nervous system neoplasm	8.45e-05	0.000692	CcSEcCtD
Loperamide—CALM3—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.96e-05	0.000169	CbGpPWpGaD
Loperamide—CALM2—Membrane Trafficking—AKT1—peripheral nervous system neoplasm	1.95e-05	0.000169	CbGpPWpGaD
Loperamide—CALM1—Membrane Trafficking—AKT1—peripheral nervous system neoplasm	1.95e-05	0.000169	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.94e-05	0.000168	CbGpPWpGaD
Loperamide—CALM3—Signaling by Wnt—MYC—peripheral nervous system neoplasm	1.93e-05	0.000167	CbGpPWpGaD
Loperamide—CALM2—B Cell Activation—AKT1—peripheral nervous system neoplasm	1.91e-05	0.000165	CbGpPWpGaD
Loperamide—CALM1—B Cell Activation—AKT1—peripheral nervous system neoplasm	1.91e-05	0.000165	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.89e-05	0.000164	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.89e-05	0.000164	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	1.89e-05	0.000164	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.87e-05	0.000162	CbGpPWpGaD
Loperamide—CALM2—Signaling by Wnt—MYC—peripheral nervous system neoplasm	1.87e-05	0.000162	CbGpPWpGaD
Loperamide—CALM1—Signaling by Wnt—MYC—peripheral nervous system neoplasm	1.87e-05	0.000162	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	1.86e-05	0.000161	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—BCHE—peripheral nervous system neoplasm	1.85e-05	0.00016	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	1.83e-05	0.000158	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	1.83e-05	0.000158	CbGpPWpGaD
Loperamide—CALM3—Metabolism—BCHE—peripheral nervous system neoplasm	1.8e-05	0.000156	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.8e-05	0.000156	CbGpPWpGaD
Loperamide—CALM3—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	1.79e-05	0.000155	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.78e-05	0.000154	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—AKT1—peripheral nervous system neoplasm	1.77e-05	0.000153	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.77e-05	0.000153	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.75e-05	0.000152	CbGpPWpGaD
Loperamide—CALM3—RNF mutants show enhanced WNT signaling and proliferation—AKT1—peripheral nervous system neoplasm	1.75e-05	0.000151	CbGpPWpGaD
Loperamide—CALM2—Metabolism—BCHE—peripheral nervous system neoplasm	1.74e-05	0.000151	CbGpPWpGaD
Loperamide—CALM1—Metabolism—BCHE—peripheral nervous system neoplasm	1.74e-05	0.000151	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—TH—peripheral nervous system neoplasm	1.74e-05	0.000151	CbGpPWpGaD
Loperamide—CALM2—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	1.73e-05	0.00015	CbGpPWpGaD
Loperamide—CALM1—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	1.73e-05	0.00015	CbGpPWpGaD
Loperamide—CALM3—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.72e-05	0.000149	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000148	CbGpPWpGaD
Loperamide—CALM3—Immune System—HGF—peripheral nervous system neoplasm	1.7e-05	0.000147	CbGpPWpGaD
Loperamide—CALM3—Metabolism—TH—peripheral nervous system neoplasm	1.69e-05	0.000147	CbGpPWpGaD
Loperamide—CALM2—RNF mutants show enhanced WNT signaling and proliferation—AKT1—peripheral nervous system neoplasm	1.69e-05	0.000146	CbGpPWpGaD
Loperamide—CALM1—RNF mutants show enhanced WNT signaling and proliferation—AKT1—peripheral nervous system neoplasm	1.69e-05	0.000146	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.69e-05	0.000146	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—HRAS—peripheral nervous system neoplasm	1.68e-05	0.000145	CbGpPWpGaD
Loperamide—CALM2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.66e-05	0.000144	CbGpPWpGaD
Loperamide—CALM1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.66e-05	0.000144	CbGpPWpGaD
Loperamide—CALM1—Immune System—HGF—peripheral nervous system neoplasm	1.65e-05	0.000143	CbGpPWpGaD
Loperamide—CALM2—Immune System—HGF—peripheral nervous system neoplasm	1.65e-05	0.000143	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—HRAS—peripheral nervous system neoplasm	1.65e-05	0.000142	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.64e-05	0.000142	CbGpPWpGaD
Loperamide—CALM1—Metabolism—TH—peripheral nervous system neoplasm	1.64e-05	0.000142	CbGpPWpGaD
Loperamide—CALM2—Metabolism—TH—peripheral nervous system neoplasm	1.64e-05	0.000142	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.63e-05	0.000141	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.63e-05	0.000141	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—HRAS—peripheral nervous system neoplasm	1.62e-05	0.000141	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—HRAS—peripheral nervous system neoplasm	1.62e-05	0.000141	CbGpPWpGaD
Loperamide—CALM3—Signaling by WNT in cancer—AKT1—peripheral nervous system neoplasm	1.62e-05	0.000141	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	1.62e-05	0.00014	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.62e-05	0.00014	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—HRAS—peripheral nervous system neoplasm	1.59e-05	0.000138	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—HRAS—peripheral nervous system neoplasm	1.59e-05	0.000138	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.58e-05	0.000136	CbGpPWpGaD
Loperamide—CALM2—Signaling by WNT in cancer—AKT1—peripheral nervous system neoplasm	1.57e-05	0.000136	CbGpPWpGaD
Loperamide—CALM1—Signaling by WNT in cancer—AKT1—peripheral nervous system neoplasm	1.57e-05	0.000136	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	1.57e-05	0.000136	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	1.57e-05	0.000136	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	1.57e-05	0.000136	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.56e-05	0.000135	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.55e-05	0.000134	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.54e-05	0.000133	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	1.52e-05	0.000132	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.52e-05	0.000132	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.52e-05	0.000131	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.5e-05	0.000129	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.5e-05	0.000129	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.5e-05	0.000129	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	1.47e-05	0.000128	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.45e-05	0.000126	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—NRAS—peripheral nervous system neoplasm	1.43e-05	0.000123	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—GNAS—peripheral nervous system neoplasm	1.42e-05	0.000123	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.41e-05	0.000122	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.41e-05	0.000122	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—ABCB1—peripheral nervous system neoplasm	1.4e-05	0.000121	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.39e-05	0.00012	CbGpPWpGaD
Loperamide—CALM3—Metabolism—GNAS—peripheral nervous system neoplasm	1.38e-05	0.00012	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—NRAS—peripheral nervous system neoplasm	1.38e-05	0.000119	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—NRAS—peripheral nervous system neoplasm	1.38e-05	0.000119	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.37e-05	0.000118	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.36e-05	0.000118	CbGpPWpGaD
Loperamide—CALM3—Metabolism—ABCB1—peripheral nervous system neoplasm	1.36e-05	0.000117	CbGpPWpGaD
Loperamide—CALM3—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	1.34e-05	0.000116	CbGpPWpGaD
Loperamide—CALM1—Metabolism—GNAS—peripheral nervous system neoplasm	1.34e-05	0.000116	CbGpPWpGaD
Loperamide—CALM2—Metabolism—GNAS—peripheral nervous system neoplasm	1.34e-05	0.000116	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.32e-05	0.000114	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.32e-05	0.000114	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.32e-05	0.000114	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.32e-05	0.000114	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.31e-05	0.000114	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.31e-05	0.000114	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.31e-05	0.000113	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.3e-05	0.000113	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.3e-05	0.000112	CbGpPWpGaD
Loperamide—CALM2—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	1.3e-05	0.000112	CbGpPWpGaD
Loperamide—CALM1—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	1.3e-05	0.000112	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	1.29e-05	0.000111	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.28e-05	0.000111	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.28e-05	0.000111	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.28e-05	0.000111	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.28e-05	0.000111	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.27e-05	0.00011	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.26e-05	0.000109	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.26e-05	0.000109	CbGpPWpGaD
Loperamide—CALM3—Immune System—PTPN11—peripheral nervous system neoplasm	1.24e-05	0.000108	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.24e-05	0.000107	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.24e-05	0.000107	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.23e-05	0.000107	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.23e-05	0.000106	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.22e-05	0.000106	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.22e-05	0.000106	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.21e-05	0.000105	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	1.21e-05	0.000105	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	1.2e-05	0.000104	CbGpPWpGaD
Loperamide—CALM2—Immune System—PTPN11—peripheral nervous system neoplasm	1.2e-05	0.000104	CbGpPWpGaD
Loperamide—CALM1—Immune System—PTPN11—peripheral nervous system neoplasm	1.2e-05	0.000104	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.19e-05	0.000103	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.19e-05	0.000103	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	1.18e-05	0.000102	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.16e-05	0.0001	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.15e-05	9.97e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTPN11—peripheral nervous system neoplasm	1.15e-05	9.93e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.14e-05	9.9e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.12e-05	9.68e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.12e-05	9.68e-05	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.11e-05	9.63e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTPN11—peripheral nervous system neoplasm	1.11e-05	9.61e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTPN11—peripheral nervous system neoplasm	1.11e-05	9.61e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.1e-05	9.54e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TP53—peripheral nervous system neoplasm	1.09e-05	9.44e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TP53—peripheral nervous system neoplasm	1.06e-05	9.13e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TP53—peripheral nervous system neoplasm	1.06e-05	9.13e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.05e-05	9.12e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	1.05e-05	9.07e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—HRAS—peripheral nervous system neoplasm	1.04e-05	9.02e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.03e-05	8.88e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.01e-05	8.74e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—HRAS—peripheral nervous system neoplasm	1.01e-05	8.73e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—HRAS—peripheral nervous system neoplasm	1.01e-05	8.73e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	9.96e-06	8.62e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	9.88e-06	8.55e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—ERBB2—peripheral nervous system neoplasm	9.83e-06	8.5e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.82e-06	8.49e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	9.7e-06	8.39e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	9.67e-06	8.37e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—ERBB2—peripheral nervous system neoplasm	9.51e-06	8.22e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—ERBB2—peripheral nervous system neoplasm	9.51e-06	8.22e-05	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	9.4e-06	8.14e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HRAS—peripheral nervous system neoplasm	9.39e-06	8.12e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.32e-06	8.06e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.24e-06	7.99e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—AKT1—peripheral nervous system neoplasm	9.21e-06	7.97e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HRAS—peripheral nervous system neoplasm	9.09e-06	7.86e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HRAS—peripheral nervous system neoplasm	9.09e-06	7.86e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—ERBB2—peripheral nervous system neoplasm	9.07e-06	7.85e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	9.02e-06	7.8e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—AKT1—peripheral nervous system neoplasm	8.91e-06	7.71e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—AKT1—peripheral nervous system neoplasm	8.91e-06	7.71e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—ERBB2—peripheral nervous system neoplasm	8.78e-06	7.59e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—ERBB2—peripheral nervous system neoplasm	8.78e-06	7.59e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.72e-06	7.55e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	8.72e-06	7.55e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.61e-06	7.45e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	8.54e-06	7.39e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	8.42e-06	7.28e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—AKT1—peripheral nervous system neoplasm	8.29e-06	7.17e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.18e-06	7.08e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.06e-06	6.97e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.04e-06	6.96e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.03e-06	6.95e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—AKT1—peripheral nervous system neoplasm	8.02e-06	6.94e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—AKT1—peripheral nervous system neoplasm	8.02e-06	6.94e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.96e-06	6.89e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	7.92e-06	6.85e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	7.92e-06	6.85e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	7.91e-06	6.85e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.81e-06	6.76e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.78e-06	6.73e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.78e-06	6.73e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.71e-06	6.67e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.7e-06	6.66e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	7.7e-06	6.66e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—NRAS—peripheral nervous system neoplasm	7.48e-06	6.47e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.28e-06	6.29e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NRAS—peripheral nervous system neoplasm	7.23e-06	6.26e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—NRAS—peripheral nervous system neoplasm	7.23e-06	6.26e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.07e-06	6.12e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—NRAS—peripheral nervous system neoplasm	6.9e-06	5.97e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.81e-06	5.89e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.76e-06	5.85e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—NRAS—peripheral nervous system neoplasm	6.68e-06	5.78e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—NRAS—peripheral nervous system neoplasm	6.68e-06	5.78e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	6.46e-06	5.59e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MYC—peripheral nervous system neoplasm	6.43e-06	5.56e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.35e-06	5.5e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	6.34e-06	5.48e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MYC—peripheral nervous system neoplasm	6.22e-06	5.38e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MYC—peripheral nervous system neoplasm	6.22e-06	5.38e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.15e-06	5.32e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.15e-06	5.32e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.99e-06	5.18e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.97e-06	5.17e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.97e-06	5.16e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.79e-06	5.01e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.79e-06	5.01e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.77e-06	4.99e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.71e-06	4.94e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.58e-06	4.83e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.58e-06	4.83e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—HRAS—peripheral nervous system neoplasm	5.47e-06	4.73e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—HRAS—peripheral nervous system neoplasm	5.29e-06	4.58e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—HRAS—peripheral nervous system neoplasm	5.29e-06	4.58e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.29e-06	4.57e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.11e-06	4.42e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.11e-06	4.42e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—HRAS—peripheral nervous system neoplasm	5.05e-06	4.37e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.05e-06	4.36e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—HRAS—peripheral nervous system neoplasm	4.89e-06	4.23e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—HRAS—peripheral nervous system neoplasm	4.89e-06	4.23e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.83e-06	4.18e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—AKT1—peripheral nervous system neoplasm	4.83e-06	4.18e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.68e-06	4.05e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.68e-06	4.05e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—AKT1—peripheral nervous system neoplasm	4.67e-06	4.04e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—AKT1—peripheral nervous system neoplasm	4.67e-06	4.04e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.5e-06	3.9e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—AKT1—peripheral nervous system neoplasm	4.46e-06	3.86e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.36e-06	3.77e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.36e-06	3.77e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—AKT1—peripheral nervous system neoplasm	4.31e-06	3.73e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—AKT1—peripheral nervous system neoplasm	4.31e-06	3.73e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—AKT1—peripheral nervous system neoplasm	3.84e-06	3.32e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—AKT1—peripheral nervous system neoplasm	3.73e-06	3.23e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.7e-06	3.2e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—AKT1—peripheral nervous system neoplasm	3.61e-06	3.13e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—AKT1—peripheral nervous system neoplasm	3.61e-06	3.13e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.58e-06	3.09e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.58e-06	3.09e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.54e-06	3.06e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.42e-06	2.96e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.42e-06	2.96e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	3.25e-06	2.81e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.12e-06	2.7e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.02e-06	2.61e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.02e-06	2.61e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.83e-06	2.45e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	2.67e-06	2.31e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.74e-06	1.51e-05	CbGpPWpGaD
